Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris
AK El Tal, MR Posner, Z Spigelman… - Journal of the American …, 2006 - Elsevier
BACKGROUND: Rituximab is an anti-CD20 chimeric antibody that selectively targets B
lymphocytes. Recently, it has been reported to be beneficial in treating pemphigus vulgaris.
OBJECTIVE: Our aim was to review the English-language literature on the treatment of
pemphigus vulgaris (PV) with rituximab and to determine its efficacy and influence on
clinical outcome (s). MATERIAL AND METHODS: A retrospective review of the literature on
the use of rituximab in the treatment of PV was conducted. Seventeen patients in 10 reports …
lymphocytes. Recently, it has been reported to be beneficial in treating pemphigus vulgaris.
OBJECTIVE: Our aim was to review the English-language literature on the treatment of
pemphigus vulgaris (PV) with rituximab and to determine its efficacy and influence on
clinical outcome (s). MATERIAL AND METHODS: A retrospective review of the literature on
the use of rituximab in the treatment of PV was conducted. Seventeen patients in 10 reports …
